Abstract

CLC Number:

R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/

https://zgywjj.magtechjournal.com/EN/Y2016/V13/I10/635

[1] 尹预真,叶丽霖,杨静,等.重组人血小板生成素联合重组人白介素-11治疗恶性肿瘤放化疗胡血小板下降的临床效果[J].武汉大学学报(医学版), 2014, 35(6):967-968.
[2] 王凤云,孔凡良.重组人白介素-11应用白血病化疗后血小板减少疗效观察[J].安徽医药, 2015, 19 (9):1816-1817.
[3] Suliman M I, Qayum I, Saeed F. Randomized clinical trial of human interleukin-11 in Dengue fever-associated thrombocytopenia[J].J Coll Physicians Surg Pak, 2014, 24(3):164-168.
[4] 余胜珠,杨光华,陈连生,等.注射用重组人白介素-11衍生物治疗恶性肿瘤化疗后血小板减少24例[J].中国药业, 2013,22(9):32-33.
[5] 李政华,姚俊涛,胡玉琴,等.重组人白介素-11(Ⅰ)(百杰依)治疗恶性肿瘤化疗后血小板减少症13例临床观察[J].现代肿瘤医学, 2015, 23(6):850-852.
[6] Xu D H, Zhu Z, Wakefield M R et al. The role of IL-11 in immunity and cancer[J]. Cancer Lett, 2016, 373(2):156-163.
[7] 陈芳君,张丹,王增,等.重组人白介素-11(Ⅰ)与重组人促血小板生成素治疗化疗相关血小板减少的经济学评价[J].中国药师,2015, 18(2):250-252.
[8] 苗文春,蒋志相,董晓燕,等.注射用重组人白介素-11所致心脏毒性的临床观察[J].实用药物与临床, 2014, 17(7):849-852.
[9] 李静,廖大忠.重组人白介素-11衍生物对恶性肿瘤患者化疗后血小板减少及不良反应的临床研究[J].临床医药文献电子杂志, 2015, 2(23):4763-4764.
[10] 韩灵敏,韩春山,宋华.恶性肿瘤患者重组人白介素-11治疗后心律失常12例临床观察[J].癌症进展, 2012, 10(2):179-181.
[11] 朱爱华.1例重组人白介素-11致低血压性休克患者的抢救与护理体会[J]．中国实用医药, 2012, 7(1):213-214.
[12] 林晓龙,陈义松,方芳.rhIL-11治疗吉西他滨化疗相关性低血小板血症致毛细血管渗漏综合征(CLS)1例[J].复旦学报(医学版), 2014, 41(2):284.

[1]	LI Xinying, BAO Lei, LI Shuran, ZHAO Ronghua, SUN Jing, XIE Dan, BAO Yanyan, GUO Shanshan, CUI Xiaolan, GENG Zihan. Effect of Shufeng Jiedu Capsules on the Production of Specific Antibodies against Influenza A H1N1 Virus and the Mechanisms [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 841-850.
[2]	WANG Xinwei, PENG Yifeng, SUN Jing, JI Zuen, BAO Lei, LUO Henglei, GENG Zihan, ZHANG Hujuan, LI Shuran, ZHANG Jingsheng, GUO Shanshan, CUI Xiaolan, ZHAO Ronghua. Effect of Yiye Anti-Influenza Capsules on Pneumonia Induced by Human Coronavirus 229E Infection in Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 851-855.
[3]	XIE Rui, SUN Qiyue, LI Yanying, ZHANG Jingsheng, ZHAO Ronghua, GUO Shanshan, GENG Zihan, BAO Lei, GAO Shuangrong, CUI Xiaolan, XIE Dan, SUN Jing. Impacts of Shuangshenling Granules on a Cadmium-Induced Chronic Renal Failure Model of Mice [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 856-862.
[4]	CHEN Siying, DING Xueli, LIU Shujia, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian. Modeling for Prediction of Cardiotoxicity of Chinese Herbal Medicines [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 869-875.
[5]	CAI Haili, ZHANG Xiaomeng, LIU Yadi, CHEN Lijuan, WANG Yu, ZHANG Bing. Preventive Strategies for Anthracycline-Induced Cardiotoxicity Using Traditional Chinese Medicine via Ferroptosis Regulation [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 876-882.
[6]	ZHENG Haiyun, WANG Zhigang, WU Hongwei, WANG Shaonan, WANG Bin. Identification of in vitro and in vivo Chemical Constituents of Buxin Anmian Decoction Based on UPLC-Q Exactive Orbitrap HRMS [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 883-888.
[7]	SUN Ya, WANG Xu, SUN Zhi, ZHOU Yubing. Dose Analysis of Linezolid in Severe Patients with Sepsis Complicated with Acute Kidney Injury [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 889-895.
[8]	SHI Qi, WANG Jianxin, WANG Guijie, LU Yueyang, ZHU Jiaxu, GAO Rui. Adjuvant Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Qingqi Huatan Pills: a Systematic Review [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 914-919.
[9]	YING Jie, XU Xiaolong, LI Bo, LIU Tengwen, LIU Qingquan. Clinical Applications of Jinhua Qinggan Granules in the Treatment of Mild Influenza: a Meta-Analysis [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 920-923.
[10]	KE Xiuqin, HAI Xuewu. 433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
[11]	LIANG Jie. 172 Cases of Adverse Drug Reactions Induced by Antineoplastic Drugs [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 928-932.
[12]	LIU Jiang, CHEN Jie, QIU Sihong, LI Na, ZHOU Ying, CHEN Yonggang, LUO Ji. Analysis of Adverse Drug Event Induced by Omacycline and Moxifloxacin Based on FAERS Databse [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 933-936.
[13]	ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing. Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
[14]	ZHOU Yujie, HUANG Xiaojing, CHEN Mingyue, DU Pengqiang, WANG Aifeng. Two Cases of Severe Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 941-943.
[15]	CHEN Huabao, LIU Wei, JIANG Ting, ZHENG Lingli, LI Jing. One Case of Acute Withdrawal Syndrome Caused by Naloxone [J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 944-946.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics